← Back to Clinical Trials
Recruiting NCT05251415

NCT05251415 Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05251415
Status Recruiting
Phase
Sponsor University Hospital, Toulouse
Condition Lupus Erythematosus
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2022-04-04
Primary Completion 2027-04-04

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 99 Years
Study Type OBSERVATIONAL
Interventions
Blood sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2022-04-04 with a primary completion date of 2027-04-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies

Eligibility Criteria

Inclusion Criteria: * Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example), * Patients with atypical presentations of documented or probable systemic autoimmune diseases, * Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.). Exclusion Criteria: * Known anemia and hemoglobin \<10 g / dl * Patients under protective supervision (guardianship, curators) * Pregnant or breastfeeding woman

Contact & Investigator

Central Contact

Chloé BOST, MD, PhD

✉ bost.c@chu-toulouse.fr

📞 5 61 77 61 44

Principal Investigator

Chloé BOST, MD, PhD

PRINCIPAL INVESTIGATOR

University Hospital, Toulouse

Frequently Asked Questions

Who can join the NCT05251415 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 99 Years, studying Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05251415 currently recruiting?

Yes, NCT05251415 is actively recruiting participants. Contact the research team at bost.c@chu-toulouse.fr for enrollment information.

Where is the NCT05251415 trial being conducted?

This trial is being conducted at Toulouse, France.

Who is sponsoring the NCT05251415 clinical trial?

NCT05251415 is sponsored by University Hospital, Toulouse. The principal investigator is Chloé BOST, MD, PhD at University Hospital, Toulouse. The trial plans to enroll 3,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology